Machine-learning derived identification of prognostic signature to forecast head and neck squamous cell carcinoma prognosis and drug response

被引:0
|
作者
Li, Sha-Zhou [1 ]
Sun, Hai-Ying [1 ]
Tian, Yuan [2 ]
Zhou, Liu-Qing [1 ]
Zhou, Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Hubei, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
machine learning; HNSCC; DEGs; tumor microenvironment; immunotherapy; CETUXIMAB; RECURRENT;
D O I
10.3389/fimmu.2024.1469895
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous malignancy is often associated with unfavorable prognosis. Due to its unique anatomical position and the absence of effective early inspection methods, surgical intervention alone is frequently inadequate for achieving complete remission. Therefore, the identification of reliable biomarker is crucial to enhance the accuracy of screening and treatment strategies for HNSCC.Method To develop and identify a machine learning-derived prognostic model (MLDPM) for HNSCC, ten machine learning algorithms, namely CoxBoost, elastic network (Enet), generalized boosted regression modeling (GBM), Lasso, Ridge, partial least squares regression for Cox (plsRcox), random survival forest (RSF), stepwise Cox, supervised principal components (SuperPC), and survival support vector machine (survival-SVM), along with 81 algorithm combinations were utilized. Time-dependent receiver operating characteristics (ROC) curves and Kaplan-Meier analysis can effectively assess the model's predictive performance. Validation was performed through a nomogram, calibration curves, univariate and multivariate Cox analysis. Further analyses included immunological profiling and gene set enrichment analyses (GSEA). Additionally, the prediction of 50% inhibitory concentration (IC50) of potential drugs between groups was determined.Results From analyses in the HNSCC tissues and normal tissues, we found 536 differentially expressed genes (DEGs). Subsequent univariate-cox regression analysis narrowed this list to 18 genes. A robust risk model, outperforming other clinical signatures, was then constructed using machine learning techniques. The MLDPM indicated that high-risk scores showed a greater propensity for immune escape and reduced survival rates. Dasatinib and 7 medicine showed the superior sensitivity to the high-risk NHSCC, which had potential to the clinical.Conclusions The construction of MLDPM effectively eliminated artificial bias by utilizing 101 algorithm combinations. This model demonstrated high accuracy in predicting HNSCC outcomes and has the potential to identify novel therapeutic targets for HNSCC patients, thus offering significant advancements in personalized treatment strategies.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Identification of PANoptosis-related biomarkers and analysis of prognostic values in head and neck squamous cell carcinoma
    Yang, Ping
    Huang, Guangzhao
    Li, Yulin
    Yu, Lang
    Yin, Zili
    Li, Qian
    SCIENTIFIC REPORTS, 2024, 14 (01): : 9824
  • [42] Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma
    Zhou, Chongchang
    Wang, Shumin
    Shen, Zhisen
    Shen, Yiming
    Li, Qun
    Shen, Yi
    Huang, Juntao
    Deng, Hongxia
    Ye, Dong
    Zhan, Guowen
    Li, Jinyun
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (01)
  • [43] Identification of an immune-related signature as a prognostic classifier for patients with early-stage head and neck squamous cell carcinoma
    Wang, Le
    Zhang, Yulin
    Li, Hongmin
    Peng, Jilin
    Gao, Changhui
    Yu, Qiuning
    Gao, Pei
    Li, Ling
    Chen, Kuisheng
    Ye, Fanglei
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (03) : 1367 - 1381
  • [44] Identification of several senescence-associated genes signature in head and neck squamous cell carcinoma
    Wang, Jian
    Zhou, Chong-Chang
    Sun, Hong-Cun
    Li, Qun
    Hu, Jian-Dao
    Jiang, Tao
    Zhou, Shao
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (07)
  • [45] A novel hypoxia-associated gene signature for prognosis prediction in head and neck squamous cell carcinoma
    Jingyi Luo
    Yuejiao Huang
    Jiahe Wu
    Lin Dai
    Mingyou Dong
    Bo Cheng
    BMC Oral Health, 23
  • [46] A novel hypoxia-associated gene signature for prognosis prediction in head and neck squamous cell carcinoma
    Luo, Jingyi
    Huang, Yuejiao
    Wu, Jiahe
    Dai, Lin
    Dong, Mingyou
    Cheng, Bo
    BMC ORAL HEALTH, 2023, 23 (01)
  • [47] Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature for head and neck squamous cell carcinoma
    Dong, Lei
    Sun, Qi
    Song, Fei
    Song, Xiaoyu
    Lu, Congxian
    Li, Yumei
    Song, Xicheng
    HELIYON, 2023, 9 (03)
  • [48] Prognostic Value of Eight-Gene Signature in Head and Neck Squamous Carcinoma
    Liu, Baoling
    Su, Quanping
    Ma, Jianhua
    Chen, Cheng
    Wang, Lijuan
    Che, Fengyuan
    Heng, Xueyuan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma
    Pan, Xue
    Xu, Xun
    Wang, Lixuan
    Zhang, Siyuan
    Chen, Yingyao
    Yang, Rongchun
    Chen, Xijuan
    Cheng, Bin
    Xia, Juan
    Ren, Xianyue
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Construction of a necroptosis-related lncRNA signature to predict the prognosis and immune microenvironment of head and neck squamous cell carcinoma
    Huang, Juntao
    Xu, Ziqian
    Teh, Bing Mei
    Zhou, Chongchang
    Yuan, Zhechen
    Shi, Yunbin
    Shen, Yi
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (06)